Un rationnel scientifique validé avec Elotuzumab - ACHAT - OC 9€
Lors du congrès de l’ASH (American Society of Hematology), INNATE et BMS, son partenaire sur le développement de lirilumab, publient ce matin les résultats précliniques de la combinaison du composé avec elotuzumab. Combiner lirilumab, un anticorps anti-KIR, et elotuzumab semble présenter au vu de ces résultats un rationnel scientifique fort et tout particulièrement dans le Myélome Multiple. Nous intégrons cette combinaison dans le traitement du Myélome Multiple pour laquelle nous appliquons un potentiel de succès de 10% ce qui représente 0,3€ par action dans notre modèle. Nous maintenons notre recommandation à l’ACHAT à l’approche de 2015, année qui devrait révéler les résultats de phase II de lirilumab dans la Leucémie Myéloïde Aigue en monothérapie.Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.